The FilmArray respiratory virus panel detects 15 viral agents in respiratory specimens using polymerase chain reaction. We performed FilmArray respiratory viral testing in a core laboratory at a regional children's hospital that provides service 24 hours a day 7 days a week. The average and median turnaround time were 1.6 and 1.4 hours, respectively, in contrast to 7 and 6.5 hours documented 1 year previously at an on-site reference laboratory using a direct fluorescence assay (DFA) that detected 8 viral agents. During the study period, rhinovirus was detected in 20% and coronavirus in 6% of samples using FilmArray; these viruses would not have been detected with DFA. We followed 97 patients with influenza A or influenza B who received care at the emergency department (ED). Overall, 79 patients (81%) were given oseltamivir in a timely manner defined as receiving the drug in the ED, a prescription in the ED, or a prescription within 3 hours of ED discharge. Our results demonstrate that molecular technology can be successfully deployed in a nonspecialty, high-volume, multidisciplinary core laboratory.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110182PMC
http://dx.doi.org/10.1309/AJCPH7X3NLYZPHBWDOI Listing

Publication Analysis

Top Keywords

filmarray respiratory
12
core laboratory
12
respiratory viral
8
turnaround time
8
viral agents
8
implementation filmarray
4
respiratory
4
viral
4
viral panel
4
panel core
4

Similar Publications

Objective: The aim of the study was to compare the cost and clinical impact of repeating BioFire FilmArray gastrointestinal (GI) and respiratory (RP) panel assays with 3 vs 4 pathogen targets positive.

Method: We analyzed 12,027 GI and RP panels to evaluate our retesting policy, which retested panels with 3 or more detected pathogens (3-pathogen protocol) compared with the manufacturer's 4-pathogen (4-pathogen protocol) recommendation. We compared the retesting results, calculated the cost implications, and reviewed the clinical impact on antibiotic prescriptions and patient outcomes.

View Article and Find Full Text PDF

Background: Viruses are key agents causing respiratory illnesses, creating significant public health challenges worldwide. Timely identification of the responsible pathogen is crucial for effective patient management. Conventional virus detection methods in laboratories are often laborious and time-consuming, prompting the need for more efficient diagnostic techniques.

View Article and Find Full Text PDF
Article Synopsis
  • Immunofluorescence techniques for detecting HCoV-OC43 in nasopharyngeal swab specimens have not been developed before this study.
  • A human rectal adenocarcinoma cell line (HRT-18) was used to analyze specimens from patients, with positive staining in cells for HCoV-OC43 found in nine out of eleven cases where RNA was detected.
  • The study suggests that immunofluorescence staining with human serum can successfully identify replicating HCoV-OC43 in specimens, and potentially other viruses, indicating this method could be useful for broader viral detection.
View Article and Find Full Text PDF

The impact of common respiratory virus infections on adults and older individuals in the community is unclear, excluding seasonal influenza viruses. We examined FilmArray® tests performed on 1828 children aged <10 years and 10,803 adults, including cases with few respiratory symptoms, between January 2021 and June 2024. Approximately 80% of the children tested positive for ≥1 viruses, while 9.

View Article and Find Full Text PDF

Advancing respiratory virus diagnostics: integrating the nasal IFN-I score for improved viral detection.

EBioMedicine

December 2024

Joint Research Unit Civils Hospices of Lyon-bioMérieux, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, 69310, France; International Center of Research in Infectiology, Virpath Team, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, 69000, France. Electronic address:

Background: This study aimed to demonstrate the utility of the nasal Type I interferon (IFN-I) response as a marker for respiratory viral infections (RVIs) and its potential to enhance diagnosis when combined with first-line PCR tests for Influenza A/B, RSV, and SARS-CoV-2.

Methods: Nasopharyngeal swabs (NPS) from patients at Hospices Civils de Lyon (November 2022-April 2024) suspected of viral infections (n = 788) and from healthy controls (n = 53) were analysed. The IFN-I score was measured using the FILMARRAY® IFN-I pouch prototype, which detects four interferon-stimulated genes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!